340B Drug Pricing Program
Associations’ Reply in Support of Motion to Intervene - AstraZeneca v. Cochran (March 19, 2021)
American Hospital Association, 340B Health, America’s Essential Hospitals, Association of American Medical Colleges, National Association of Children’s Hospitals d/b/a Children’s Hospital Association, and American Society of HealthSystem Pharmacists (collectively the “Proposed Intervenors”) move…
Response to Motion to Intervene - SANOFI-AVENTIS vs HHS (March 22, 2021)
UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION
ELI LILLY AND COMPANY,
Lilly Corporate Center
893 Delaware Street
Indianapolis, IN 46225, et al.,
IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION
The AHA yesterday
AHA letter to Senators, John Thune, Rob Portman, Shelley Moore Capito, Tammy Baldwin, Debbie Stabenow and Ben Cardin expressing support for legislation, S. 773.
For nearly 30 years, the 340B Drug Pricing Program has provided financial help to safety-net hospitals to manage rising prescription drug costs. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted…
UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
ASTRAZENECA PHARMACEUTICALS LP
Plaintiff,
–v–